Boehringer Ingelheim USA Corporation

Boehringer Ingelheim's zongertinib showed significant objective response rate (ORR) in advanced NSCLC patients with HER2 mutations, with 66.7% ORR and 94% tumor shrinkage. The treatment was well tolerated, with no deaths reported and common AEs being rash and diarrhea.

16 new weight-loss drugs expected to enter the $200 billion market by 2031, challenging Novo Nordisk and Eli Lilly. Amgen and Pfizer among companies testing treatments. New entrants could lower prices. Potential acquisitions in the obesity sector anticipated.

Walgreens launched its clinical trial business in June 2022, leveraging its national retail pharmacy network for patient recruitment, trial conduct, and real-world evidence services. The company has expanded its services, focusing on insights-driven patient recruitment, trial conduct, and real-world evidence informatics. Walgreens has successfully enrolled diverse patient populations in various trials, addressing historical underrepresentation in research. The company aims to continue its role in decentralizing clinical research, making trials more accessible and representative.

Boehringer Ingelheim reported positive outcomes from the Beamion LUNG-1 trial, assessing zongertinib for treating NSCLC with HER2 mutations. The trial met its primary endpoint, showing a 66.7% objective response rate and a tolerable safety profile, with no treatment-related deaths.

The North America CMO and CDMO biotechnology market is robust, segmented by applications like oncology, cardiology, immunology, neurology, and metabolic diseases. Key manufacturers include Patheon, Catalent, Samsung Biologics, and Lonza. The market is driven by technological advancements and growing demand for automation, with a promising future for innovation and growth.

The Global Exosome Market: Size, Forecast, Trials, and Trends, 2024 report details the growing exosome market, highlighting advancements in diagnostics, therapeutics, and cosmetics. Exosomes, extracellular vesicles, are valuable for disease detection, diagnosis, and treatment. The market is expanding with 388 clinical trials underway, and first exosome therapeutics expected by 2029. Key players and technologies are profiled, along with market forecasts through 2030.

AstraZeneca and Daiichi Sankyo shares fell due to mixed results in a late-stage trial for their lung cancer drug Dato-DXd, which showed some patients lived longer but overall results were not statistically significant. The drug is expected to be approved based on overall survival and progression-free survival improvements.

Semaglutide injections reduced overall, cardiovascular, and infection-related deaths by 19%, 15%, and 23% respectively in a study of 17,000 obese and overweight patients with heart disease.